JOCHEN FLEISCHMANN
VICE PRESIDENT
GLOBAL THERAPEUTIC AREA MARKET ACCESS LEADER
IMMUNOLOGY
Jochen Fleischmann is the Vice President, Global Therapeutic Area Market Access Leader, Immunology, for the Janssen Pharmaceutical Companies of Johnson & Johnson. Together with his team, he oversees the creation and implementation of the Immunology global market access strategies for all compounds in the Immunology portfolio. He jointly leads integrated evidence generation with Medical Affairs team members. In partnership with the Global Commercial Strategy Organization (GCSO) Market Access hub, Research & Development, regional partners, and external stakeholders, he drives product value and shapes the payer environment and healthcare policies.
Before joining the Immunology team, he was the Global Therapeutic Area Market Access Leader for Neuroscience. In that role, Jochen was instrumental in shaping, adapting, and implementing the Market Access strategies for SPRAVATO® (esketamine) and PONVORY® (ponesimod), leading the respective teams through challenging payer environments and strongly contributing to driving forward critical initiatives. Together with his team, he has created the foundation for future Market Access success of Janssen’s Neuroscience pipeline.
Jochen began his career with Johnson & Johnson in 2006 at Janssen Germany and subsequently held several positions within Market Access and Governmental Affairs with growing responsibilities. As the Director Market Access, Health Economics and Outcomes Research in Janssen Germany from 2011 to 2015, Jochen successfully prepared the Company for the newly established AMNOG reimbursement process, leading the team through more than 10 business critical submissions, contributing substantially to establishing Janssen as the industry leading market access company in the key German market. Jochen’s experiences were enriched through cross-functional experiences in policy focused and commercial roles such as the EMEA Hematology Integrated Brand Value Team Leader, where he successfully grew the Acute Myeloid Leukemia business and prepared future assets for launch.
Jochen holds a doctoral degree in Economics and received his education in Economics and Health Economics from the University of Bayreuth, Germany, and Massey University, New Zealand.
Follow Jochen on LinkedIn here.